Literature DB >> 28949787

Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Sarah B Lloyd1, Keith P Niven2, Ben R Kiefel2, David C Montefiori3, Arnold Reynaldi4, Miles P Davenport4, Stephen J Kent1,5,6, Wendy R Winnall1.   

Abstract

While broadly neutralizing antibodies (bnAbs) are a promising preventative and therapeutic tool for HIV infection, production is difficult and expensive. Production of antibody-like fragments in bacterial cytoplasm provides a cheaper alternative. This work explored the transplantation of the complementarity determining regions of the anti-HIV bnAbs PGT121 and 10E8 onto a single-chain variable fragment (scFv) scaffold, previously discovered through a novel screening platform. The scaffolded 10E8 scFv, but not the scaffolded PGT121 scFv, was soluble in bacterial cytoplasm, enabling efficient production in bacteria. Three additional multimeric constructs employing the scaffolded 10E8 scFv were also generated and soluble versions produced in bacteria. However, the constructs were found to have substantially lost anti-HIV binding function and had completely abrogated neutralizing activity. Overall, while this study provides a proof-of-concept for anti-HIV bnAb construct production in bacterial cytoplasm, future refinement of these technologies will be required to realize the goal of producing inexpensive and effective bnAb-like tools for the control of HIV.

Entities:  

Keywords:  10E8; Broadly neutralizing antibodies; Diabodies; E. coli Expression; Human immunodeficiency virus; PGT121; Single-chain variable fragment antibodies; Tandem-scFv

Mesh:

Substances:

Year:  2017        PMID: 28949787      PMCID: PMC5703365          DOI: 10.1080/21645515.2017.1368935

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  46 in total

Review 1.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

2.  Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.

Authors:  Yasuhiro Maruta; Takeo Kuwata; Kazuki Tanaka; Muntasir Alam; Kristel Paola Ramirez Valdez; Yoshika Egami; Yoshiaki Suwa; Hiroshi Morioka; Shuzo Matsushita
Journal:  Jpn J Infect Dis       Date:  2016-02-19       Impact factor: 1.362

3.  The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies.

Authors:  Michela Visintin; Giovanni Settanni; Amos Maritan; Sergio Graziosi; James D Marks; Antonino Cattaneo
Journal:  J Mol Biol       Date:  2002-03-15       Impact factor: 5.469

4.  Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.

Authors:  Marina Caskey; Florian Klein; Michel C Nussenzweig
Journal:  N Engl J Med       Date:  2016-11-09       Impact factor: 91.245

5.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Engineering antibody fragments to fold in the absence of disulfide bonds.

Authors:  Min Jeong Seo; Ki Jun Jeong; Clinton E Leysath; Andrew D Ellington; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2009-02       Impact factor: 6.725

7.  Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection.

Authors:  Lin-Xu Wang; Michael Mellon; Dane Bowder; Meghan Quinn; Danielle Shea; Charles Wood; Shi-Hua Xiang
Journal:  Virology       Date:  2014-12-05       Impact factor: 3.616

8.  Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays.

Authors:  David C Montefiori
Journal:  Curr Protoc Immunol       Date:  2005-01

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

10.  Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2009-05-14       Impact factor: 5.328

View more
  1 in total

1.  A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.

Authors:  Melissa M Lemke; Milla R McLean; Christina Y Lee; Ester Lopez; Emily R Bozich; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Sven Kratochvil; Bruce D Wines; P Mark Hogarth; Stephen J Kent; Amy W Chung; Kelly B Arnold
Journal:  Cell Rep Med       Date:  2021-09-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.